 NEW YORK, April 26, 2021 PRNewswire -- BrainStorm Cell Therapeutics Inc. NASDAQ: BCLI, a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2021 and provided a corporate update. In the first quarter we were excited to announce positive top line data from our Phase 2 trial evaluating NurOwn as a treatment for progressive multiple sclerosis MS. 